2020 current operating income showed strong growth (+37.6% at constant rates and scope), reflecting the excellent evolution of revenue (+5.7% at constant rates and scope) and a sharp decrease in expenses in the context of the Covid-19 crisis

2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) 

Revenue grew +6.8% at constant exchange rates and scope at the end of September 2020 (+5.6% at constant rates) thanks to solid third quarter performance

Virbac will change its governance at its shareholders' meeting on December 15

Operating profit from ordinary activities up sharply for the first half of 2020 reflecting revenue resiliency and strong expenditure restraint during the Covid-19 crisis

Revenue grew by +5.0% at constant exchange rates in the first half of 2020 (+4.5% excluding Sentinel), impacted by a decline in the second quarter of the year

Virbac completes divestment of U.S. Rights to SENTINEL^® brands to MSD Animal Health

Virbac to divest U.S. Rights to SENTINEL^® brands to MSD Animal Health

2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying